Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Absci Corp
(NQ:
ABSI
)
5.210
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Absci Corp
< Previous
1
2
Next >
University of Oxford’s Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies
May 11, 2023
Absci will apply its generative AI platform to The Kennedy Institute’s immunology biorepository to speed the discovery and development of multiple therapies
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the 22nd Annual Needham Virtual Healthcare Conference
April 06, 2023
From
Absci Corporation
Via
GlobeNewswire
Absci Partners with Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology
April 04, 2023
Absci’s generative AI platform will use M2GEN’s industry-leading clinicogenomic database with the aim of creating better cancer treatments faster
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
March 30, 2023
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation
March 23, 2023
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
March 07, 2023
From
Absci Corporation
Via
GlobeNewswire
Absci Expands in Europe with Launch of New Innovation Center and Additional Senior Leadership in Switzerland
February 28, 2023
The generative AI drug company ramps up its internal pipeline and R&D portfolio, tapping into European markets, talent, and tech
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the 43rd Annual Cowen Health Care Conference
February 21, 2023
From
Absci Corporation
Via
GlobeNewswire
St. John’s Cancer Institute Partners with Absci to Expedite Development of Cancer Therapies
February 09, 2023
From
Absci Corporation
Via
GlobeNewswire
Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation
February 08, 2023
In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will strengthen Absci’s scientific leadership in...
From
Absci Corporation
Via
GlobeNewswire
Absci First to Create and Validate De Novo Antibodies with Zero-Shot Generative AI
January 10, 2023
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference
January 08, 2023
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 28, 2022
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the Berenberg Discover AI Seminar
November 23, 2022
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the Piper Sandler Healthcare Conference
November 17, 2022
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Third Quarter 2022 Financial Results
November 09, 2022
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the Stifel Healthcare Conference
November 02, 2022
From
Absci Corporation
Via
GlobeNewswire
Absci Welcomes Meta Senior Executive to Board of Directors
November 02, 2022
Technology veteran Dan Rabinovitsj provides expertise in collaborating with technology partners to catalyze innovation as Absci accelerates generative AI drug creation
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the 31st Annual Credit Suisse Healthcare Conference
October 26, 2022
From
Absci Corporation
Via
GlobeNewswire
Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer
October 04, 2022
From
Absci Corporation
Via
GlobeNewswire
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
October 06, 2021
From
EQRx and Absci
Via
Business Wire
NASDAQ:ABSI Shareholder Notice: Investigation over Potential Securities Laws Violations by Absci Corporation
September 20, 2021
San Diego, CA -- (SBWIRE) -- 09/20/2021 -- Absci Corporation are under investigation concerning potential securities laws violations in connection with certain financial statements.
Via
SBWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.